{
    "title": "AstraZeneca shares surge after key drug shows promise in lung cancer trial",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4499272/Key-AstraZeneca-drug-shown-reduce-risk-death-lung-cancer.html",
    "date": "2017-05-12",
    "keywords": [
        "trial",
        "drug",
        "cancer",
        "astrazeneca",
        "lung",
        "durvalumab",
        "imfinzi",
        "roche",
        "percent",
        "pacific",
        "alistair",
        "london",
        "business",
        "product",
        "market",
        "treatment",
        "combination",
        "chemotherapy",
        "therapy",
        "berenberg",
        "reporting",
        "astrazenecas",
        "progression",
        "companys",
        "lead",
        "oncology",
        "boost",
        "company",
        "race",
        "midafternoon",
        "ftse",
        "riser",
        "level",
        "september",
        "day",
        "merck",
        "approval",
        "surgery",
        "option",
        "sean",
        "bohen",
        "executive",
        "vice",
        "president",
        "development",
        "statement",
        "gap",
        "mid2017",
        "surprise",
        "readout",
        "inflection",
        "point",
        "immunooncology",
        "deutsche",
        "bank",
        "note",
        "theory",
        "opportunity",
        "impact",
        "loss",
        "cholesterol",
        "pill",
        "bodys",
        "immune",
        "radiation",
        "put",
        "arent",
        "efficacy",
        "sign",
        "june",
        "july",
        "importance",
        "reassurance",
        "chance",
        "month",
        "bladder",
        "green",
        "light",
        "ben",
        "hirschler",
        "humer",
        "york",
        "editing"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}